- Report
- February 2026
- 150 Pages
China
From €4573EUR$4,850USD£3,831GBP
- Report
- February 2026
- 150 Pages
Germany
From €4573EUR$4,850USD£3,831GBP
- Report
- February 2026
- 150 Pages
India
From €4573EUR$4,850USD£3,831GBP
- Report
- September 2025
- 150 Pages
Global
From €4573EUR$4,850USD£3,831GBP
- Report
- August 2025
- 150 Pages
Global
From €4573EUR$4,850USD£3,831GBP
- Report
- May 2025
- 150 Pages
Global
From €4573EUR$4,850USD£3,831GBP
- Report
- March 2025
- 150 Pages
Global
From €4573EUR$4,850USD£3,831GBP
- Report
- January 2024
- 150 Pages
Global
From €4573EUR$4,850USD£3,831GBP
- Report
- January 2024
- 150 Pages
Global
From €4573EUR$4,850USD£3,831GBP
- Report
- May 2023
- 140 Pages
Global
From €4666EUR$4,949USD£3,909GBP
- Report
- August 2026
- 160 Pages
Nigeria
From €3130EUR$3,320USD£2,622GBP
€3913EUR$4,150USD£3,278GBP
- Report
- October 2025
- 160 Pages
Global
From €2980EUR$3,160USD£2,496GBP
€3725EUR$3,950USD£3,120GBP
- Report
- July 2024
- 154 Pages
Global
From €3206EUR$3,400USD£2,685GBP
€4007EUR$4,250USD£3,357GBP
- Report
- April 2023
- 240 Pages
Global
From €3394EUR$3,600USD£2,843GBP
- Report
- April 2023
- 82 Pages
North America
From €1414EUR$1,500USD£1,185GBP
- Report
- April 2023
- 94 Pages
Africa, Middle East
From €1414EUR$1,500USD£1,185GBP
- Report
- March 2023
- 203 Pages
Global
From €3394EUR$3,600USD£2,843GBP
- Report
- March 2023
- 84 Pages
Africa, Middle East
From €1414EUR$1,500USD£1,185GBP
- Report
- March 2023
- 84 Pages
Asia Pacific
From €1414EUR$1,500USD£1,185GBP
- Report
- March 2023
- 85 Pages
Europe
From €1414EUR$1,500USD£1,185GBP

Neuropathic pain is a type of chronic pain caused by damage to the nervous system. It is often described as a burning, tingling, or shooting sensation. Analgesics are medications used to reduce or eliminate pain. Neuropathic pain is often treated with a combination of analgesics, including non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and anticonvulsants. Other treatments may include physical therapy, nerve blocks, and electrical stimulation.
The neuropathic pain market is a rapidly growing segment of the analgesics market. It is driven by the increasing prevalence of chronic pain conditions, such as diabetes, cancer, and multiple sclerosis. The market is expected to benefit from the development of novel treatments, such as gene therapy and stem cell therapy.
Some companies in the neuropathic pain market include Pfizer, Johnson & Johnson, GlaxoSmithKline, Novartis, and Eli Lilly. Show Less Read more